Key clinical point: A retrospective study suggests MYC rearrangement (MYC-R) has prognostic significance in patients with diffuse large B-cell lymphoma (DLBCL) in relation to the MYC partner gene.

Major finding: The unfavorable prognostic significance of MYC-R was majorly limited to patients with accompanying rearrangement of BCL2 and/or BCL6 translocations (MYC double-hit/triple-hit status) and an immunoglobulin (IG) partner (hazard ratio, 2.4; 95% confidence interval, 1.6-3.6; P less than .001).

Study details: A retrospective cohort study of 2,383 patients with DLBCL who were evaluable for MYC-R.

Disclosures: The study was supported by unrestricted grants to the Lunenburg Lymphoma Biomarker Consortium from several pharmaceutical companies and Bloodwise. Dr. Rosenwald reported having no conflicts of interest, but several coauthors reported relationships with industry.